2,3,6-三氟苯磺酰氯 | 1017779-75-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3,6-三氟苯磺酰氯
• 英文名称: 2,3,6-Trifluorobenzenesulfonyl chloride
• CAS: 1017779-75-7
• 化学式: C₆H₂ClF₃O₂S
• mdl: MFCD09832391
• 分子量: 230.59
• InChiKey: IFFKHMGJJCDTJL-UHFFFAOYSA-N

物化性质

• 沸点：
  220.7±35.0 °C(Predicted)
• 密度：
  1.662±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  CORROSIVE
• 危险等级：
  8

文献信息

• Novel Sulfonaminoquinoline Hepcidin Antagonists
  申请人：Buhr Wilm

  公开号：US20120214803A1

  公开（公告）日：2012-08-23

  The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

  本发明涉及新型肝铁蛋白拮抗剂，包括它们的药物组合物以及将其用作药物治疗铁代谢紊乱，特别是铁缺乏病和贫血等疾病，特别是与慢性炎症性疾病相关的贫血。
• New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes
  申请人：Amrein Kurt

  公开号：US20060025455A1

  公开（公告）日：2006-02-02

  Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof used in the form of pharmaceutical compositions.

  化合物的化学式(I)：以及其药用可接受的盐和酯，用于制成药物组合物。
• FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF
  申请人：NISSAN CHEMICAL INDUSTRIES, LTD.

  公开号：US20190031600A1

  公开（公告）日：2019-01-31

  Provided is a fluorine atom-containing compound represented by formula (1) below (In the formula, Z represents a predetermined divalent group, each Ar independently represents a predetermined aromatic ring-containing group, and each Ar F independently represents a predetermined fluorine atom-containing aryl group).

  提供的是下面公式（1）所代表的含氟原子的化合物（在公式中，Z代表预定的二价基团，每个Ar独立代表预定的含芳香环的基团，每个ArF独立代表预定的含氟原子的芳基基团）。
• PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：Xu Weizheng

  公开号：US20090098084A1

  公开（公告）日：2009-04-16

  The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.

  本发明涉及四氮杂苯并-3-酮化合物，其抑制聚(ADP-核糖)聚合酶(PARP)并在化疗敏感性中有用。周围神经病是许多传统和新型化疗药物的常见副作用。本发明进一步提供可靠预防或治愈化疗诱导的神经病的方法。本发明还涉及使用所披露的PARP抑制剂化合物来增强化疗药物如替莫唑胺的疗效。本发明还涉及使用所披露的PARP抑制剂化合物来使肿瘤细胞对电离辐射产生放射敏化作用。本发明还涉及使用所披露的PARP抑制剂化合物治疗DNA修复缺陷的癌症。
• Compounds for inhibiting insulin secretion and methods related thereto
  申请人：Pei Yazhong

  公开号：US20060004062A1

  公开（公告）日：2006-01-05

  Compounds, compositions and methods for altering insulin secretion, particularly in the context of treatment of subjects having, or suspected of being at risk for having, diabetes mellitus. The compounds have the following struture (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein W 1 , W 2 , X, R 1 , R 2 , R 3 , R 4 , m and n are defined herein.

  这是一篇关于改变胰岛素分泌的化合物、组合物和方法的文章，特别是在治疗已经患有或者疑似患有糖尿病的患者中。这些化合物的结构如下（I）：包括立体异构体、前药和药用可接受的盐，其中W1、W2、X、R1、R2、R3、R4、m和n在此定义。